CATT of course tested ranibizumab (Lucentis) as the control against bevacizumab (Avastin) and not aflibercept (Eylea) against bevacizumab (Lucentis).
Apologies. I was too late to edit my above post.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-37
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
42.8¢ |
Change
0.018(4.27%) |
Mkt cap ! $529.3M |
Open | High | Low | Value | Volume |
42.0¢ | 44.0¢ | 42.0¢ | $299.9K | 705.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 179911 | 42.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.0¢ | 75350 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 180730 | 0.425 |
10 | 140397 | 0.420 |
9 | 210837 | 0.415 |
15 | 409578 | 0.410 |
10 | 328279 | 0.405 |
Price($) | Vol. | No. |
---|---|---|
0.430 | 75350 | 10 |
0.435 | 142801 | 11 |
0.440 | 16377 | 5 |
0.445 | 51491 | 7 |
0.450 | 258677 | 5 |
Last trade - 12.26pm 29/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |